PMID- 37678728
OWN - NLM
STAT- MEDLINE
DCOM- 20231030
LR  - 20231030
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 204
DP  - 2023 Oct
TI  - Glycemic control metrics in a cohort of hospitalized patients with type 1 
      diabetes using hybrid closed-loop and advanced hybrid closed-loop systems.
PG  - 110897
LID - S0168-8227(23)00660-5 [pii]
LID - 10.1016/j.diabres.2023.110897 [doi]
AB  - AIMS: To describe Hybrid closed-loop (HCL) and advanced hybrid closed-loop (AHCL) 
      performance in the hospital setting based on the continuous glucose monitoring 
      (CGM) metrics description. METHODS: This was an observational study from a cohort 
      of patients with T1D using HCL/AHCL with history of hospitalization. CGM metrics 
      were analyzed during the hospital stay. CGM metrics sub-analysis of the 
      population with active Automated Mode (AM) and SmartGuard (SG) during 
      hospitalization and/or surgical procedure was performed. RESULTS: Twenty-four 
      patients were included (50 % women; mean age, 49 years [inter-quartile range 
      (IQR), 39-62 years]). During hospitalization 70.8 % patients achieved %Time in 
      Range (TIR) between 70 and 180 mg/dL >/= 70 %. The overall %TIR was 75.5 % (IQR, 
      67.3-81.5 %), % time below range (TBR) < 70 mg/dL was 2.1 % (IQR, 0.7-5.4 %) and 
      %TBR < 54 mg/dL was 0 % (IQR, 0-5.4 %). Users of the AHCL with active SG achieved 
      a non-significant higher %TIR during hospitalization (79 % [73.8.88 %] vs. 76 % 
      [72.81 %], p = 0.312) and had a shorter stay (3[IQR, 2.4] vs. 6 days[IQR, 5.7], 
      p = 0.045) compared to the users of the HCL with AM active. No device-related 
      serious adverse events occurred for users of either system. CONCLUSIONS: HCL/AHCL 
      systems with active AM/SG in patients with T1D in the hospital environment leads 
      to %TIR > 70 % in ranges of 70-180 mg/dL in patients without increasing 
      hypoglycemia.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Gomez Medina, Ana Maria
AU  - Gomez Medina AM
AD  - Endocrinology Unit, Hospital Universitario San Ignacio, Carrera 7 # 45-62, 
      Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 
      40-62, Colombia. Electronic address: anagomez@javeriana.edu.co.
FAU - Henao-Carrillo, Diana Cristina
AU  - Henao-Carrillo DC
AD  - Endocrinology Unit, Hospital Universitario San Ignacio, Carrera 7 # 45-62, 
      Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 
      40-62, Colombia. Electronic address: d-henao@javeriana.edu.co.
FAU - Yepes, Carlos
AU  - Yepes C
AD  - Endocrinology Unit, Hospital Universitario San Ignacio, Carrera 7 # 45-62, 
      Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 
      40-62, Colombia. Electronic address: cayepes@husi.org.co.
FAU - Silva, Julio
AU  - Silva J
AD  - Endocrinology Unit, Hospital Universitario San Ignacio, Carrera 7 # 45-62, 
      Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 
      40-62, Colombia. Electronic address: silvaljd@javeriana.edu.co.
FAU - Gomez Gonzalez, Javier Alberto
AU  - Gomez Gonzalez JA
AD  - Endocrinology Unit, Hospital Universitario San Ignacio, Carrera 7 # 45-62, 
      Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 
      40-62, Colombia. Electronic address: jalbertogomezg@javeriana.edu.co.
FAU - Cortes, David
AU  - Cortes D
AD  - Endocrinology Unit, Hospital Universitario San Ignacio, Carrera 7 # 45-62, 
      Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 
      40-62, Colombia. Electronic address: david-cortes@juanncorpas.edu.co.
FAU - Robledo, Sofia
AU  - Robledo S
AD  - Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 40-62, 
      Colombia. Electronic address: s.robledo@javeriana.edu.co.
FAU - Mejia, Gabriela
AU  - Mejia G
AD  - Faculty of Medicine, Pontificia Universidad Javeriana, Carrera 7 # 40-62, 
      Colombia. Electronic address: gabriela.mejiap@javeriana.edu.co.
FAU - Rondon, Martin
AU  - Rondon M
AD  - Department of Epidemiology, Pontificia Universidad Javeriana, Carrera 7 # 40-62, 
      Colombia. Electronic address: martin.rondon@javeriana.edu.co.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230905
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - *Diabetes Mellitus, Type 1/drug therapy
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - Glycemic Control
MH  - Hospitalization
MH  - Insulin
MH  - Hypoglycemic Agents
MH  - Insulin Infusion Systems
OTO - NOTNLM
OT  - Automated insulin delivery
OT  - Hospital
OT  - Time in range
OT  - Type 1 diabetes
COIS- Declaration of Competing Interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: AMG reports speaker fees from Novo Nordisk, Sanofi, Elli Lilly, 
      Boehringer Ingelheim, Abbott and Medtronic. DCH reports speaker fees from Novo 
      Nordisk, Sanofi and Abbott.
EDAT- 2023/09/08 00:41
MHDA- 2023/10/30 06:46
CRDT- 2023/09/07 19:30
PHST- 2023/07/11 00:00 [received]
PHST- 2023/08/25 00:00 [revised]
PHST- 2023/09/04 00:00 [accepted]
PHST- 2023/10/30 06:46 [medline]
PHST- 2023/09/08 00:41 [pubmed]
PHST- 2023/09/07 19:30 [entrez]
AID - S0168-8227(23)00660-5 [pii]
AID - 10.1016/j.diabres.2023.110897 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2023 Oct;204:110897. doi: 10.1016/j.diabres.2023.110897. 
      Epub 2023 Sep 5.